Abstract
De novo lymphangiogenesis influences different pathological courses via modulating tissue fluid homeostasis, macromolecule absorption, and leukocyte transmigration. During the past decade, improved understanding of lymphatic biology, especially VEGF-C/- D/VEGFR-3-mediating lymphangiogenesis has substantially promoted clinical research in lymphatic insufficiency. The role of lymphangiogenesis in the setting of the inflammatory processes observed in transplants, inflamed cornea, wound healing, acquired lymphedema and tumor invasion, however, remains to be elucidated. The chemokine family of peptide chemoattractants and other mediators, e.g., CCL21-CCR7, D6, NF-κB and TNF-α may be important contributors to pathophysiological changes of lymphatic endothelial cells (LECs) and inflammatory lymphangiogenesis. Dendritic cells and macrophages may also involve in LEC proliferation and differentiation. Increased knowledge of LEC-specific modulators in inflammatory microenvironment is vital for prevention and treatment of lymphatic- associated diseases.
Keywords: Lymphatic endothelial cells, lymphangiogenesis, inflammation, VEGF-C/-D/VEGFR-3, CCL21-CCR7, D6, NF-κB, TNF-α
Current Medicinal Chemistry
Title: Lymphatic Endothelial Cells, Inflammatory Lymphangiogenesis, and Prospective Players
Volume: 14 Issue: 22
Author(s): R. C. Ji
Affiliation:
Keywords: Lymphatic endothelial cells, lymphangiogenesis, inflammation, VEGF-C/-D/VEGFR-3, CCL21-CCR7, D6, NF-κB, TNF-α
Abstract: De novo lymphangiogenesis influences different pathological courses via modulating tissue fluid homeostasis, macromolecule absorption, and leukocyte transmigration. During the past decade, improved understanding of lymphatic biology, especially VEGF-C/- D/VEGFR-3-mediating lymphangiogenesis has substantially promoted clinical research in lymphatic insufficiency. The role of lymphangiogenesis in the setting of the inflammatory processes observed in transplants, inflamed cornea, wound healing, acquired lymphedema and tumor invasion, however, remains to be elucidated. The chemokine family of peptide chemoattractants and other mediators, e.g., CCL21-CCR7, D6, NF-κB and TNF-α may be important contributors to pathophysiological changes of lymphatic endothelial cells (LECs) and inflammatory lymphangiogenesis. Dendritic cells and macrophages may also involve in LEC proliferation and differentiation. Increased knowledge of LEC-specific modulators in inflammatory microenvironment is vital for prevention and treatment of lymphatic- associated diseases.
Export Options
About this article
Cite this article as:
Ji C. R., Lymphatic Endothelial Cells, Inflammatory Lymphangiogenesis, and Prospective Players, Current Medicinal Chemistry 2007; 14 (22) . https://dx.doi.org/10.2174/092986707781745541
DOI https://dx.doi.org/10.2174/092986707781745541 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Immunomodulatory Drugs (IMiDs) in Multiple Myeloma
Current Cancer Drug Targets Hsp70 Molecular Chaperones: Emerging Roles in Human Disease and Identification of Small Molecule Modulators
Current Topics in Medicinal Chemistry Major Challenges for Gene Therapy of Thalassemia and Sickle Cell Disease
Current Gene Therapy Establishment of a Primary Screening Assay for the DHX9 Helicase
Combinatorial Chemistry & High Throughput Screening A Comparison of Biological Activity of B Lymphocyte Stimulator (BLyS) Antagonist Peptibodies and the Elucidation of Possible BLyS Binding Sites
Protein & Peptide Letters Practical Approach to Children Presenting with Eosinophila and Hypereosinophilia
Current Pediatric Reviews One Special Question to Start with: Can HIF/NFkB be a Target in Inflammation?
Endocrine, Metabolic & Immune Disorders - Drug Targets Next Generation Sequencing in Non-Small Cell Lung Cancer: New Avenues Toward the Personalized Medicine
Current Drug Targets Observations on the Use of the Avian Chorioallantoic Membrane (CAM) Model in Investigations into Angiogenesis
Current Drug Targets - Cardiovascular & Hematological Disorders Isolation, Purification, Characterisation and Application of L-ASNase: A Review
Recent Patents on Biotechnology Population Based Helicobacter pylori Screening and Eradication: Advances Versus Side Effects
Current Pharmaceutical Design Drug Delivery Approaches for Doxorubicin in the Management of Cancers
Current Cancer Therapy Reviews Herpes Simplex Virus Type 1 Amplicons and their Hybrid Virus Partners, EBV, AAV, and Retrovirus
Current Gene Therapy Preferentially Expressed Antigen in Melanoma (PRAME) and the PRAME Family of Leucine-Rich Repeat Proteins
Current Cancer Drug Targets Individualized Treatment Planning in Oncology: Role of PET and Radiolabelled Anticancer Drugs in Predicting Tumour Resistance
Current Pharmaceutical Design Natural Antibodies: Protecting Role of IgM in Glioblastoma and Brain Tumours
Current Pharmaceutical Design PARP Inhibitor Development for Systemic Cancer Targeting
Anti-Cancer Agents in Medicinal Chemistry Benzothiazole: A Versatile and Multitargeted Pharmacophore in the Field of Medicinal Chemistry
Letters in Organic Chemistry NF-κB in Systemic Lupus Erythematosus and Antiphospholipid Syndrome
Current Rheumatology Reviews Poly(ADP-Ribose) Polymerase Inhibitors: New Pharmacological Functions and Potential Clinical Implications
Current Pharmaceutical Design